Phase III randomized, multicenter open label study to evaluate the efficacy of immunomodulatory therapy in case of psychiatric disorders with proven dysimmunity. - TIM-DEPIST

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2022
This article has no abstract
Epistemonikos ID: 4af0db7ca745be9aadf1b46e5b82cec8b6702271
First added on: Apr 17, 2025